Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q33970582)
Watch
English
Current and future directions in medical therapy for breast carcinoma: endocrine treatment
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
review article
1 reference
stated in
Europe PubMed Central
title
Current and future directions in medical therapy for breast carcinoma: endocrine treatment
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
main subject
breast carcinoma
1 reference
based on heuristic
inferred from title
author name string
Pritchard KI
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
language of work or name
English
0 references
publication date
1 June 2000
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
published in
Cancer
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
volume
88
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
issue
12 Suppl
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
page(s)
3065-3072
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
cites work
Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
The Christie hospital adjuvant tamoxifen trial--status at 10 years
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Ovarian ablation in early breast cancer: phoenix arisen?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
The value of estrogen and progesterone receptors in the treatment of breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2F1097-0142%2820000615%2988%3A12%2B%3C3065%3A%3AAID-CNCR25%3E3.0.CO%3B2-P
retrieved
21 January 2018
Identifiers
DOI
10.1002/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
Fatcat ID
release_f66lq34q75gwlmue4ec44ioodm
1 reference
stated in
Fatcat
reference URL
https://api.fatcat.wiki/v0/release/f66lq34q75gwlmue4ec44ioodm
retrieved
24 November 2022
based on heuristic
mapped directly with Wikidata item
PubMed ID
10898353
1 reference
stated in
Europe PubMed Central
PubMed ID
10898353
retrieved
30 July 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit